REGULATIONS
Rulings
AD/CVD
Notices
HTSUS
U.S. Code
Regs
More
Ports
About
Updates
Apps
Larger font
Smaller font
CustomsMobile Pro
beta now open!
Apply for a FREE beta account. Spaces are limited so apply today.
SIGNUP FOR BETA
SEARCH
Sort by Rank
Titles Ascending
Titles Descending
10 per page
25 Result/page
50 Result/page
Regulations last checked for updates: Nov 22, 2024
Title 21 - Food and Drugs last revised: Nov 19, 2024
All Titles
Title 21
Chapter I
Part 201
Subpart G - Subpart G—Specific Labeling Requirements for Specific Drug Products
§ 201.300 - Notice to manufacturers, packers, and distributors of glandular preparations.
§ 201.301 - Notice to manufacturers, packers, and distributors of estrogenic hormone preparations.
§ 201.302 - Notice to manufacturers, packers, and distributors of drugs for internal use which contain mineral oil.
§ 201.303 - Labeling of drug preparations containing significant proportions of wintergreen oil.
§ 201.304 - Tannic acid and barium enema preparations.
§ 201.305 - Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human use; warnings.
§ 201.306 - Potassium salt preparations intended for oral ingestion by man.
§ 201.307 - Sodium phosphates; package size limitation, warnings, and directions for over-the-counter sale.
§ 201.308 - Ipecac syrup; warnings and directions for use for over-the-counter sale.
§ 201.309 - Acetophenetidin (phenacetin)-containing preparations; necessary warning statement.
§ 201.310 - Phenindione; labeling of drug preparations intended for use by man.
§ 201.311 - [Reserved]
§ 201.312 - Magnesium sulfate heptahydrate; label declaration on drug products.
§ 201.313 - Estradiol labeling.
§ 201.314 - Labeling of drug preparations containing salicylates.
§ 201.315 - Over-the-counter drugs for minor sore throats; suggested warning.
§ 201.316 - Drugs with thyroid hormone activity for human use; required warning.
§ 201.317 - Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning.
§ 201.319 - Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil tragacanth, and xanthan gum) as active ingredients; required warnings and directions.
§ 201.320 - Warning statements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances.
§ 201.323 - Aluminum in large and small volume parenterals used in total parenteral nutrition.
§ 201.325 - Over-the-counter drugs for vaginal contraceptive and spermicide use containing nonoxynol 9 as the active ingredient; required warnings and labeling information.
§ 201.326 - Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling.
§ 201.327 - Over-the-counter sunscreen drug products; required labeling based on effectiveness testing.
§ 201.328 - Labeling of medical gas containers.
Appendix Appendix A - Appendix A to Part 201—Examples of Graphic Enhancements Used by FDA
authority:
21 U.S.C. 321
,
331
,
343
,
351
,
352
,
353
,
355
,
358
,
360
,
360
b,
360
ccc,
360
ccc-1,
360
ee,
360
gg-360ss,
371
,
374
,
379e
;
42 U.S.C. 216
,
241
,
262
,
264
source:
40 FR 13998, Mar. 27, 1975, unless otherwise noted.
.list_box li,p,.cm-search-info,.cm-search-detail,.abt span,.expand-collapse_top
Get the CustomsMobile app!